1. New Ways to Do Science (And Maybe Change the World) Stephen M. Maurer Goldman School of Public Policy Maurer@econ.berkeley.edu

4. Coverage Curation Updating Responsiveness Open Science

6. Curated & Updated Coverage Computationally Powerful Responsiveness Open Science √ √ √ √ √ Academic Commercial

9. Swiss Prot Table of Isotopes

10. GDB HGMD

11. The SNP Consortium Mutations Database Initiative; Data Delivery, Content, Ads, Alert Services, etc.

12. Communities Governments A Chilling Effect?

13. Which Hybrids Are Acceptable? Social Scientists Can Help! Limits of Open Science Ideology vs. Institutions Cutting Across Sectors Money

14. Traffic Builders Advertisements Alert Services Data Delivery MDI

15. Updates & Embargoes “Premium” Versions “Reasonable” Academic Rates

20. A New Community Goal A New Research Institution Intervening in Commercial Sector Taking the Literature Seriously

21. Investment Based on Price Signal Elicits Private Information Moral Risk: Researchers Moral Risk: Sponsors Monopoly Pricing Are the Remaining Risks Manageable?

27. A New Mode of Production Why It Works Ideology Education Reputation Job Prospects In Silico Biology

28. History: The Sabin & Salk Vaccines Would Big Pharma Play? And Would It Matter?

31. Investment Based on Price Signal Elicits Private Information Moral Risk: Researchers Moral Risk: Sponsors Monopoly Pricing

32. Investment Based on Price Signal Elicits Private Information Avoids Monopoly Pricing Avoids Moral Risk: Researchers Avoids Moral Risk: Sponsors √√√

33. Investment Based on Price Signal Elicits Private Information √√ Avoids Monopoly Pricing Avoids Moral Risk: Researchers Avoids Moral Risk: Sponsors

34. Investment Based on Price Signal Elicits Private Information √√ √√ √ √ √ Avoids Monopoly Pricing Avoids Moral Risk: Researchers Avoids Moral Risk: Sponsors

35. Investment Based on Price Signal Ideology Education Reputation Building Job Hunting Government & Foundations

36. Investment Based on Price Signal Elicits Private Information √√ √√ √ √ √ Avoids Monopoly Pricing Avoids Moral Risk: Researchers Avoids Moral Risk: Sponsors

37. Avoids Monopoly Pricing Avoids Moral Risk: Sponsors √√ √ √

39. Investment Based on Price Signal Elicits Private Information √√ √√ √ √ √ Avoids Monopoly Pricing Avoids Moral Risk: Researchers Avoids Moral Risk: Sponsors

40. Elicits Private Information √ Databases & Advice Good Will & Politics Price Discrimination

41. Investment Based on Price Signal Elicits Private Information √√ √√ √ √ √ Avoids Monopoly Pricing Avoids Moral Risk: Researchers Avoids Moral Risk: Sponsors

42. Avoids Moral Risk: Researchers √ √ Existing Regulation

43. Investment Based on Price Signal Elicits Private Information √√ √√ √ √ √ Avoids Monopoly Pricing Avoids Moral Risk: Researchers Avoids Moral Risk: Sponsors

45. S. Maurer, “Inside the Anticommons: Academic Scientists’ Struggle to Commercialize Human Mutations Data, 1999-2001,” preliminary version available at http://emlab.berkeley.edu/users/bhhall/ ipconf/maurer01.pdf S. Maurer, “Promoting and Disseminating Knowledge: The Public/Private Interface,” a report for US National Academy of Sciences (2002), available at http://www7.nationalacademies.org/biso/Ma urer_background_paper.html

46. Prof. Suzanne Scotchmer, UC Berkeley (Economics, Public Policy). “Procuring Knowledge,” NBER Working Paper 9903 Available at www.nber.org.

47. Prof. Arti Rai, Duke University School of Law Prof. Andrej Sali, California Institute for Quantitative Biomedical Research, UC San Francisco

48. New Ways to Do Science (And Maybe Change the World) Stephen M. Maurer Goldman School of Public Policy Maurer@econ.berkeley.edu